Urology
Volume 68, Issue 6 , Pages 1169-1174 , December 2006

Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli

  • Javier Ena

      Affiliations

    • Department of Internal Medicine, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
    • Corresponding Author InformationReprint requests: Javier Ena, M.D., Servicio de Medicina Internal Hospital Marina Baixa, Av Alcalde En Jaume Botella Mayor, 7, Villajoyosa, Alicante 03570 Spain.
    • ,
  • Francisco Arjona

      Affiliations

    • Clinical Microbiology Laboratory, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
    • ,
  • Carmen Martínez-Peinado

      Affiliations

    • Clinical Microbiology Laboratory, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
    • ,
  • Maria del mar López-Perezagua

      Affiliations

    • Clinical Microbiology Laboratory, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
    • ,
  • Concepción Amador

      Affiliations

    • Department of Internal Medicine, Hospital Marina Baixa, Villajoyosa, Alicante, Spain

Received 14 February 2006 ,Accepted 17 August 2006.

References 

  1. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infection due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206–2212
  2. Centers for Disease Control and Prevention: Laboratory detection of extended-spectrum β-lactamases (ESBLs). Available at: http://www.cdc.gov/ncidod/hip/Lab/FactSheet/esbl.htm. Accessed November 30, 2002.
  3. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281:517–523
  4. Kanafani ZA, Mehio-Sibai A, Araj GF, et al. Epidemiology and risk factors for extended-spectrum β-lactamase producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326–332
  5. Goldstein FW Multicenter Study Group. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis. 2000;19:112–117
  6. Hryniewicz K, Szcypa K, Sulikowska A, et al. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother. 2001;47:773–780
  7. Rodriguez-Baño J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by expended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–1094
  8. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–167
  9. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251
  10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, 12th Informational Supplement. Wayne, PA: NCCLS; 2002;NCCLS document M100-S12.
  11. Jarlier V, Nicolas MH, Fournier G, et al. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10:867–878
  12. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York: Oxford University Press; 1982;
  13. Winokur PL, Canton R, Casellas JM, et al. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis. 2001;32(suppl 2):S94–S103
  14. Itokazu GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996;23:779–784
  15. Hyle EP, Lipworth AD, Zaoutis TE, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing enterobacteriaceae. Arch Intern Med. 2005;165:1375–1380
  16. Navon-Venezia S, Ben-Ami R, Schwaber MJ, et al. Protocol for the accelerated detection of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains from blood cultures. Eur J Clin Microbiol Infect Dis. 2004;23:200–202
  17. Yagüe A, Cebrian L, Rodriguez-Diaz JC, et al. Expanded-spectrum beta-lactamase-producing strains of E. coli: origin, characteristics and incidence in southern Alicante (Spain) in the period 1999–2003. Enferm Infecc Microbiol Clin. 2005;23:76–79
  18. Andreu A, Alos JI, Gobernado M, et al. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study. Enferm Infecc Microbiol Clin. 2005;23:4–9
  19. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–1171
  20. Walker S, McGeer A, Simor AE, et al. Why are antibiotics prescribed for asymptomatic bacteriuria in institutionalized elderly people?. Can Med Assoc J. 2000;163:273–277

PII: S0090-4295(06)02070-X

doi: 10.1016/j.urology.2006.08.1075

Urology
Volume 68, Issue 6 , Pages 1169-1174 , December 2006

Article Tools